Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
$795.57
$8.96(1.38%)
At close: 4:00 PM EST
$795.57
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $934.62
Previous CloseN/A
Volume151.62K
Average Volume (3M)283.48K
Market Cap
$50.44B
Enterprise Value$31.60B
Total Cash (Recent Filing)$3.93B
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)37.4
Beta0.24
Next Earnings
Feb 26, 2026EPS Estimate
5.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.18
Shares Outstanding61,883,408
10 Day Avg. Volume255,140
30 Day Avg. Volume283,477
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.70
Price to Sales (P/S)16.81
P/FCF Ratio-243.71
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue13.77
Enterprise Value/Gross Profit20.81
Enterprise Value/Ebitda49.33
Forecast
1Y Price Target
$1,041.18Price Target Upside30.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial MomentumStrong launch momentum for Vyvgart in generalized myasthenia gravis and CIDP, supported by a scalable commercial infrastructure and a newly hired chief commercialization officer, could drive continued sales expansion.
Leadership ContinuityPromotion of the chief operating officer to chief executive officer while the outgoing CEO becomes non-executive chair preserves commercial leadership and institutional knowledge, reducing disruption during the executive transition.
Pipeline Clinical CatalystsMultiple late-stage readouts for Vyvgart follow-on indications and empasiprubart, together with a planned registrational study for Graves' disease in early 2026, create opportunities for meaningful market expansion if trials succeed.
Bears Say
Analyst Conflict Of InterestExisting business relationships between research firms and covered companies create potential conflicts that may undermine perceived objectivity of analyst reports and affect investor confidence.
Clinical Trial DiscontinuationDiscontinuation of the phase 3 UplighTED studies for thyroid eye disease after a futility analysis constitutes a material clinical setback that lowers near-term pipeline optionality.
Valuation And Execution RiskStretched market expectations, lowered platform valuation and reduced sales estimates increase vulnerability to downside if upcoming clinical results or commercialization execution fall short.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $934.62 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $50.44B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 26, 2026 which is in 47 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 30, 2025. The company reported $5.18 earnings per share for the quarter, beating the consensus estimate of $4.488 by $0.692.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 5.98.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,883,408 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $5.18 in its last earnings report, beating expectations of $4.488. Following the earnings report the stock price went down -0.196%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,041.18 (30.87% Upside)
$1,041.18 (30.87% Upside)
Blogger Sentiment
Neutral
ARGX Sentiment 57%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 116.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 25.0%
Last 30 Days ▲ 25.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.53%
12-Months-Change
Fundamentals
Return on Equity
24.75%
Trailing 12-Months
Asset Growth
49.60%
Trailing 12-Months
Company Description
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX Company Deck
ARGX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly the PFS, alongside significant pipeline progress. However, there were setbacks in certain pipeline developments and increased operating expenses. Despite this, the positives of revenue growth and successful commercial strategies outweigh the negatives.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$1,041.18
▲(30.87% Upside)
Technical Analysis
Ownership Overview
―
Insiders
18.95% Mutual Funds
17.59% Other Institutional Investors
62.28% Public Companies and Individual Investors